Skip to main content
. 2023 Feb 9;329(8):640–650. doi: 10.1001/jama.2023.0550

Figure 2. Distribution of Modified Rankin Scale Scores at 90 Days in the Full Analysis Set.

Figure 2.

A total of 760 patients were included in the full analysis set; however, 696 patients (329 in the argatroban plus alteplase group and 367 in the alteplase alone group) with 90-day follow-up data were included in the analysis of the primary outcome. The raw distribution of scores is shown. Scores ranged from 0 to 6, with 0 indicating no symptoms; 1, symptoms without clinically significant disability; 2, slight disability; 3, moderate disability; 4, moderately severe disability; 5, severe disability; and 6, death. Treatment with argatroban plus alteplase was associated with an adjusted risk difference of −1.0% (95% CI, −7.6% to 5.7%; P = .78) for the outcome of a score of 0 or 1 on the modified Rankin Scale at 90 days. The overall distribution of scores was not statistically significant in the ordinal logistic analysis (odds ratio, 1.06 [95% CI, 0.81-1.39]; P = .66; adjusted odds ratio, 1.01 [95% CI, 0.58-1.76]; P = .98).